CCNB2 Human
Description
Introduction to CCNB2 Human
Cyclin B2 (CCNB2) is a regulatory protein encoded by the CCNB2 gene in humans, belonging to the B-type cyclin family. It plays a pivotal role in controlling the transition from the G2 phase to mitosis (G2/M) during the cell cycle by forming a complex with cyclin-dependent kinase 1 (CDK1). This complex, termed maturation-promoting factor (MPF), ensures proper cell division and genomic stability . Dysregulation of CCNB2 is implicated in cancer progression, neurodegenerative diseases, and ischemic events, making it a critical focus of biomedical research .
3.1. Cellular Localization and Interactions
CCNB2 localizes to the Golgi apparatus, distinguishing it from Cyclin B1 (microtubule-associated). It interacts with:
-
TGF-β RII: Modulates transforming growth factor-beta signaling, linking cell cycle control to extracellular cues .
3.2. Role in Disease Pathways
-
Cancer: Overexpression of CCNB2 correlates with poor prognosis in gastric cancer (GC), triple-negative breast cancer (TNBC), and low-grade glioma (LGG) .
-
Cerebral Ischemic Stroke (CIS): Upregulated CCNB2 exacerbates neuronal damage via CDK5-mediated pathways .
4.1. Expression Analysis Across Cancers
CCNB2 is overexpressed in 16+ cancer types, including:
4.2. Mechanistic Insights
-
Cell Cycle Dysregulation: CCNB2 overexpression accelerates G2/M transition, promoting uncontrolled proliferation .
-
PI3K/AKT Pathway Activation: In GC, CCNB2 upregulates RHBDL2, driving epithelial-mesenchymal transition (EMT) and metastasis .
-
Immune Microregulation: In LGG, CCNB2 correlates with B-cell infiltration, suggesting immunomodulatory roles .
5.1. Biomarker Utility
-
Diagnostic Accuracy: AUC = 0.911 in GC, outperforming conventional markers .
-
Prognostic Value: High CCNB2 levels predict shorter survival in hepatocellular carcinoma (HR = 2.1) and prostate cancer .
5.2. Targeted Therapies
-
Knockdown Studies: Silencing CCNB2 inhibits GC cell proliferation and migration in vitro and in vivo .
-
CDK Inhibitors: Preclinical models show efficacy in TNBC and gliomas .
Future Directions
-
Clinical Trials: Validate CCNB2-targeted therapies (e.g., CDK inhibitors) in phase I/II trials.
-
Multi-Omics Integration: Explore CCNB2’s role in immune evasion using single-cell RNA sequencing .
-
Cross-Disease Pathways: Investigate shared mechanisms between cancer and ischemic stroke via CCNB2-driven cell cycle anomalies .
Product Specs
Product Science Overview
Cyclin-B2 is a protein that in humans is encoded by the CCNB2 gene located on chromosome 15 (15q22.2) . The recombinant form of Cyclin-B2 is often produced in Escherichia coli and purified using conventional chromatography techniques . The recombinant protein typically includes an N-terminal His-tag to facilitate purification and detection .
Cyclin-B2 associates with CDK1 (Cyclin-dependent kinase 1) to form a serine/threonine kinase holoenzyme complex known as the maturation promoting factor (MPF) . This complex is pivotal for the progression of cells from the G2 phase to the M phase of the cell cycle . Cyclin-B2 is primarily associated with the Golgi region, differentiating it from Cyclin-B1, which co-localizes with microtubules .
Cyclin-B2 is involved in several key cellular processes:
- Cell Cycle Regulation: It regulates the G2/M transition, ensuring proper cell division .
- Protein Interactions: Cyclin-B2 interacts with transforming growth factor beta receptor 2 (TGFβR2), playing a role in TGFβ-mediated cell cycle control .
- Subcellular Localization: Its association with the Golgi apparatus suggests a role in Golgi-related functions during cell division .
